Abstract

Randomized Controlled Trial of Cognitive-Behavioral and Mindfulness-Based Stress Reduction on the Quality of Life of Patients With Crohn Disease

Inflamm Bowel Dis. 2021 Apr 13;izab083. doi: 10.1093/ibd/izab083. Online ahead of print.

Ganit Goren 1, Doron Schwartz 2 3, Michael Friger 4, Hagar Banai 5 6, Ruslan Sergienko 3, Shirley Regev 1, Heba Abu-Kaf 2 3, Dan Greenberg 7, Anna Nemirovsky 6, Karny Ilan 8, Livnat Lerner 8, Alon Monsonego 8, Iris Dotan 5 6, Henit Yanai 5 6, Rami Eliakim 6 9, Shomron Ben Horin 6 9, Vered Slonim-Nevo 1, Shmuel Odes 3, Orly Sarid 1

 
     

Author information

  • 1Spitzer Department of Social Work, Ben-Gurion University of the Negev, Beer Sheva, Israel.
  • 2Department of Gastroenterology and Hepatology, Soroka Medical Center, Beer Sheva, Israel.
  • 3Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
  • 4Department of Public Health, Ben-Gurion University of the Negev, Beer Sheva, Israel.
  • 5Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel.
  • 6Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • 7Department of Health Systems Management, School of Public Health, Guilford Glazer Faculty of Business and Management, Ben-Gurion University of the Negev, Beer Sheva, Israel.
  • 8The Shraga Segal Department of Microbiology and Immunology, Faculty of Health Sciences, The National Institute for Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • 9Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Israel.

Abstract

Background: Patients with Crohn disease have debilitating psychological symptoms, mental fatigue, and poor quality of life. Psychological intervention may improve these symptoms.

Methods: We performed a randomized parallel-group physician-blinded trial of cognitive-behavioral and mindfulness-based stress reduction (COBMINDEX) on quality of life and psychological symptoms in adults with mild-moderate Crohn disease. COBMINDEX was taught by social workers in one-on-one video conferences over 3 months; quotidian home practice was mandated.

Results: Fifty-five COBMINDEX and 61 waitlist control patients completed the study; mean age was 33 years and 65% of participants were women. At 3 months, COBMINDEX patients had significantly reduced disease activity (per Harvey-Bradshaw Index score, C-reactive protein level, and calprotectin level), increased quality of life (Short Inflammatory Bowel Disease Questionnaire [SIBDQ] score increased from baseline 41 to 50; P < 0.001), decreased psychological symptoms (Global Severity Index [GSI], 0.98-0.70; P < 0.001), reduced fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue, 26-33; P < 0.001), and increased mindfulness disposition (Freiburg Mindfulness Inventory, 33-38; P < 0.001). Waitlist patients had a significant but small change in Harvey-Bradshaw Index, SIBDQ, and GSI scores, without improvement in fatigue or mindfulness. There were significant correlations (0.02 > P < 0.002) in COBMINDEX patients between baseline SIBDQ, GSI, Freiburg Mindfulness Inventory, and Functional Assessment of Chronic Illness Therapy-Fatigue scores with a relative change (baseline to 3 months) of the SIBDQ score, but none among waitlist patients. Predictors of relative change of the SIBDQ score in COBMINDEX patients included the GSI score (90% quantile; coefficient 0.52; P < 0.001), somatization (90%; 0.20; P = 0.001), depression (75%; 0.16; P = 0.03), and phobic anxiety (75%; 0.31; P = 0.008).

Conclusions: COBMINDEX was effective in increasing patients' quality of life and reducing psychological symptoms and fatigue. Patients with severe baseline psychological symptoms benefited the most from COBMINDEX.

© Copyright 2013-2021 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.